Please assess the completion status of the following clinical trial:

Trial Title: Michelangelo - Oasis 5

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting or admitted to hospital with symptoms suspected to represent an acute coronary syndrome.~* Able to randomize within 24 hours of the onset of the most recent episode of symptoms.~* At least one of the following additional criteria: (1) Troponin T of I or CK-MB above the upper limit of normal for the local institution and/or (2) ECG changes compatible with ischemia~* Written informed consent~Exclusion Criteria:~* Age \< 21 years~* Any contraindication to low molecular weight heparin~* Hemorrhagic stroke within the last 12 months~* Indication for anticoagulation other than ACS.~* Pregnancy or women of childbearing potential who are not using an effective method of contraception~* Co-morbid condition with life expectancy less than 6 months~* Prior enrollment in one of the fondaparinux ACS trails or currently receiving an experimental pharmacologic agent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: ACTIVE_COMPARATOR): None
- Fondaparinux (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).